Please login to the form below

Not currently logged in
Email:
Password:

Forxiga

This page shows the latest Forxiga news and features for those working in and with pharma, biotech and healthcare.

PMCPA takes AZ to task over asthma drug press release

PMCPA takes AZ to task over asthma drug press release

company in Amsterdam last November relating to SGLT2 inhibitor diabetes drugs and specifically its Forxiga (dapagliflozin) product.

Latest news

  • AZ data suggest SGLT2 inhibitors can reduce heart failure risk AZ data suggest SGLT2 inhibitors can reduce heart failure risk

    AZ data suggest SGLT2 inhibitors can reduce heart failure risk. Publishes real-world data for study involving Forxiga/Farxiga, Invokana and Jardiance. ... Now, AZ's study suggests that benefit is reproduced in a generalised, real-world setting and that

  • Merck & Co and Pfizer take aim at diabetes with trio of new drugs Merck & Co and Pfizer take aim at diabetes with trio of new drugs

    The first SGLT2 inhibitor to be approved in the US was Johnson &Johnson's Invokana (canagliflozin) in 2013, while in Europe it was AstraZeneca's Forxiga/Farxiga (dapagliflozin) the previous year. ... J&J's Invokana franchise brought in $1.4bn in sales

  • New Jardiance label could boost sales by $1.7bn, says analyst New Jardiance label could boost sales by $1.7bn, says analyst

    Another SGLT1 inhibitor - Bristol-Myers Squibb/AstraZeneca's Forxiga/Farxiga (dapagliflozin) - is also in a cardiovascular outcomes trial that is not due to generate results until 2019.

  • AstraZeneca's Forxiga set to be recommended by NICE AstraZeneca's Forxiga set to be recommended by NICE

    AstraZeneca's Forxiga set to be recommended by NICE. The type 2 diabetes ‘ triple therapy’ is backed in draft guidance. ... The firm is looking to expand Forxiga into kidney disease and heart failure, where it has begun recruitment for phase II trials

  • AZ looks beyond diabetes with Forxiga trials AZ looks beyond diabetes with Forxiga trials

    AZ looks beyond diabetes with Forxiga trials. Will investigate dapagliflozin in kidney disease and heart failure. ... AstraZeneca has started a clinical trial programme to try to extend the use of its diabetes drug Forxiga into kidney disease and heart

More from news
Approximately 16 fully matching, plus 49 partially matching documents found.

Latest Intelligence

  • Made in China Made in China

    targeted lung cancer drug Tagrisso and diabetes treatment Forxiga.

  • Market dynamics, marketing and analytics Market dynamics, marketing and analytics

    Secondly, growth is ebbing away from Forxiga (dapagliflozin), the first entrant of the DPP4s, which is actually growing slightly slower than Trajenta. ... Forxiga and Invokana (canagliflozin) appear to be reaching a plateau but at different lower levels.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... The potential

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics